Trial Profile
A Two Part, Multiple Dose Clinical Trial of the Safety and Efficacy of ABX-EGF [panitumumab] in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 02 Oct 2005 New trial record.
- 31 Mar 2003 Recruitment completed, according to results published in the Thoracic Oncology.